Teicoplanin Prophylaxis for Total Hip or Knee Arthroplasty

This study has been completed.
Sponsor:
Collaborator:
KAT Hospital of Athens
Information provided by:
University of Athens
ClinicalTrials.gov Identifier:
NCT00719056
First received: July 14, 2008
Last updated: July 18, 2008
Last verified: July 2008
  Purpose

This is a prospective, open-label, randomized clinical trial where patients were administered prophylaxis for total hip or knee arthroplasty either with teicoplanin or with other antibiotics. The study is aiming to evaluate any differences between these two different strategies of antimicrobial prophylaxis in the occurrence of surgical site infections


Condition Intervention Phase
Total Hip and Knee Arthroplasties
Drug: Teicoplanin
Drug: β-lactams or ciprofloxacin
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Efficacy of Teicoplanin for the Prevention of Surgical Site Infections After Total Hip or Knee Arthroplasty: A Prospective, Open-Label Randomized Study

Resource links provided by NLM:


Further study details as provided by University of Athens:

Primary Outcome Measures:
  • To compare the efficacy of single dose teicoplanin compared with comparator agents in the prevention of surgical site infections after total hip or knee arthroplasty. [ Time Frame: Two years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To compare the efficacy of single dose teicoplanin compared with comparator agents in the separate prevention of superficial or deep surgical site infections after total hip or knee arthroplasty. [ Time Frame: Two years ] [ Designated as safety issue: No ]

Enrollment: 616
Study Start Date: August 2004
Study Completion Date: December 2007
Primary Completion Date: December 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Surgical chemoprophylaxis of one dose of teicoplanin upon introduction of anesthesia for total hip or knee arthroplasty.
Drug: Teicoplanin
The selected dose was 10mg/kg and it was given intravenously by a catheter inserted under aseptic conditions in a forearm vein within 15 minutes; it was diluted in one 5% glucose solution of a 50 ml final volume
Other Name: Glycopeptide
Active Comparator: 2
Surgical chemoprophylaxis with multiple dose of other antimicrobials for up to six consecutive days for total hip or knee arthroplasty.
Drug: β-lactams or ciprofloxacin
Multiple doses for up to six consecutive days
Other Name: Cephalosporins or ciprofloxacin or penicillincs

Detailed Description:

This is a prospective, open-label, randomized clinical trial where patients were administered prophylaxis for total hip or knee arthroplasty either with a single dose of teicoplanin or with multiple doses of other antibiotics according to the habits of the attending physicians aiming to evaluate any differences between these two different strategies of antimicrobial prophylaxis in the occurrence of surgical site infections

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients admitted for total hip arthroplasty
  • Patients admitted for total knee arthroplasty

Exclusion Criteria:

  • Revision arthroplasty
  • History of any infection within the preceding two months
  • History of an operation in the same hip or knee for other causes
  • Known history of allergy to the studied drug
  • Pregnancy or lactation
  • Any antibiotic therapy in the week before operation.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00719056

Locations
Greece
2nd Department of Orthopedics, KAT Hospital
Maroussi, Athens, Greece, 14527
3rd Department of Orthopedics, KAT Hospital
Maroussi, Athens, Greece, 14527
4th Department of Orthopedics, KAT Hospital
Maroussi, Athens, Greece, 14527
Sponsors and Collaborators
University of Athens
KAT Hospital of Athens
Investigators
Study Chair: Helen Giamarellou, MD, PhD 4th Department of Internal Medicine, University of Athens, Medical School, Greece
Principal Investigator: Amyntas Varvaroussis, MD 3rd Department of Orthopedics, KAT Hospital, Maroussi, Greece
Principal Investigator: Panagiotis Papadelis, MD 2nd Department of Orthopedics, KAT Hospital, Maroussi, Greece
Principal Investigator: Vassilios Nikolaidis, MD 4th Department of Orthopedics, KAT Hospital, Maroussi, Greece
Study Director: Antonios Papadopoulos, MD, PhD 4th Department of Internal Medicine, University of Athens, Medical School, Greece
  More Information

Publications:
Responsible Party: University of Athens, Medical School, Greece
ClinicalTrials.gov Identifier: NCT00719056     History of Changes
Other Study ID Numbers: TEICO01
Study First Received: July 14, 2008
Last Updated: July 18, 2008
Health Authority: Greece: National Organization of Medicines

Keywords provided by University of Athens:
teicoplanin
prophylaxis
arthroplasty
surgical site infections

Additional relevant MeSH terms:
Ciprofloxacin
Teicoplanin
Cephalosporins
Anti-Bacterial Agents
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents

ClinicalTrials.gov processed this record on September 14, 2014